CONTEXT: This is a serious amount of data that OM1 have managed to amass on Rheumatoid Arthritis patients, with over 200,000 adults and over 5000 juveniles being followed in registries. We look forward to the positive impact that analysis of all this data will bring.
IMPACT: Medium
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 7
1. “Additionally, researchers can tap into data from another 1.6 million RA patients and 58,000 JIA patients in the OM1 Real-World Data Cloud™, which can be used for modelling, analytics, and other research purposes.”
2. “BOSTON, April 20, 2021 /PRNewswire/ — OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, announced its Rheumatoid Arthritis (RA) registry now includes longitudinal clinical data from rheumatology specialists on more than 200,000 patients.”
3. “With a mean follow-up of 6 years, the OM1 RA (200,000+ patients) and JIA (5,000+ patients) registries enable the continuous follow-up of key information for accelerating medical research, evaluating comparative outcomes and personalizing medicine, including clinical, laboratory and other data, such as measures of steroid dosing, treatment response and patient reported outcomes.”
4. “For more information, Hurley. Head of Marketing, OM1. With a focus on chronic conditions, OM1 is a real-world data, outcomes and technology company leveraging big clinical data and AI to better understand, compare, and predict patient outcomes.”
5. “OM1’s real-world evidence platform, clinical registries and AI technologies enable clients to accelerate research, measure and benchmark health outcomes and to personalize patient care.”